Adjuvant colon cancer chemotherapy: Is there an Indian standard of care?

South Asian J Cancer · 2013 · PMC3876667 · PMID 24455556

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The X-ACT study compared capecitabine and iv 5-FU/LV Mayo clinic regimen in patients with resected Stage III disease, and showed a trend towards superiority of capecitabine in both DFS (HR 0.87, CI 0.75-1.0) and overall survival (HR 0.84, CI 0.69-1.01).[ 13 ] Oxaliplatin, irinotecan, and biological agents have shown benefit in the metastatic setting and were thus studied in the adjuvant setting.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.